Aclaris Therapeutics, Inc. (ACRS)

NMS – Цена в реальном времени. Валюта: USD

5.87

-0.05 (-0.84%)

Рынок открыт: Aug 12, 2026, 1:00 PM EDT

6.04

+0.12 (2.03%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

10.08.2026

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

06.08.2026

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive LP, cutaneous LP, and lichen planopilaris. Aclaris expects to initiate a phased multi-part Phase 2b trial of modzatinib in LP in the fourth quarter of 2026.

06.08.2026

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.13 per share a year ago.

06.08.2026

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Timelines Reaffirmed for Upcoming Top Line Results from Phase 1b Proof-of-Concept (POC) Trials of ATI-052 and Phase 2 Trial of Bosakitug (ATI-045) - - Strong Cash Runway Expected to Enable Development of Pipeline Through the End of 2028 - WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2026 and provided a corporate and clinical update.

Видео

No Data

There is no data to display

Пресс-релизы

06.08.2026

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

06.08.2026

Aclaris Therapeutics, Inc. (ACRS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Aclaris Therapeutics, Inc. (ACRS)

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Видео

No Data

Пресс-релизы

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Видео

No Data

Пресс-релизы

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Search stocks

Aclaris Therapeutics, Inc. (ACRS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Aclaris Therapeutics, Inc. (ACRS)

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Видео

No Data

Пресс-релизы

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Видео

No Data

Пресс-релизы

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update